Trial of Dasatinib in Advanced Sarcomas

Trial ID or NCT#

NCT00464620

Status

not recruiting iconNOT RECRUITING

Purpose

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Official Title

A Phase II Trial of Dasatinib in Advanced Sarcomas

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
650-498-7061

View on ClinicalTrials.gov